Skip to main content

Advertisement

SpringerLink
Log in

Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experience

  • CHEST RADIOLOGY
  • Published:
La radiologia medica Aims and scope Submit manuscript

Abstract

Background

Several experiences in the literature report SBRT as an effective treatment option for medically inoperable early stage non-small cell lung cancer (NSCLC) and oligometastatic disease. The optimal fractionation schedules and total dose remain controversial. In this study, we evaluated the safety in terms of toxicity and efficacy of using of 8–10 fractions schedules with Helical Tomotherapy (HT) for primary and metastatic lung lesions.

Methods

Between March 2014 and May 2016, a total of 39 patients (median age 72 years, range 26–91) were treated with HT-SBRT for malignant lung lesions: 22 patients with early stage NSCLC, 17 with oligometastases. Patients received 8–10 fractions with lower daily dose for central and ultracentral lesions. Treatment-related toxicity was evaluated using CTCAE v 4.0 scale. Local control (LC), overall survival (OS) and toxicity rates were prospectively collected.

Results

Median duration of RT was 15 days (range 10–26 days) and no interruption occurred. With a median follow-up of 13 months (range 3–29), we reported one G2 pneumonitis (2.6%) and one G2 chest pain (2.6%); no ≥ G2 esophagitis was registered. Actuarial local control rate was 95.5% both at 12 and 24 months for early stage NSCLC and 92.9% both at 12 and 24 months for metastatic patients. OS rate was 94.4 and 92.3% at 1 year, and 94.4 and 83.9% at 2 years in primary and metastatic group, respectively.

Conclusions

The use of 8–10 fractions schedule HT-SBRT for lung malignancies results in high LC and OS rates with minimal toxicities reported.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, Simo GV, Vansteenkiste J, Peters S, ESMO Guidelines Committee (2016) Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v1–v27

    Article  PubMed  CAS  Google Scholar 

  2. Ricardi U, Frezza G, Filippi AR, Badellino S, Levis M, Navarria P, Salvi F, Marcenaro M, Trovò M, Guarneri A, Corvò R, Scorsetti M (2014) Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study. Lung Cancer 84(3):248–253. https://doi.org/10.1016/j.lungcan.2014.02.015 (Epub 2014 Mar 13)

    Article  PubMed  Google Scholar 

  3. Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S (2010) Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 28(35):5153–5159. https://doi.org/10.1200/JCO.2010.30.0731 (Epub 2010 Nov 1)

    Article  PubMed  Google Scholar 

  4. Chang JY, Balter PA, Dong L, Yang Q, Liao Z, Jeter M, Bucci MK, McAleer MF, Mehran RJ, Roth JA, Komaki R (2008) Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 72(4):967–971. https://doi.org/10.1016/j.ijrobp.2008.08.001

    Article  PubMed  PubMed Central  Google Scholar 

  5. Verstegen NE, Oosterhuis JWA, Palma DA, Rodrigues G, Lagerwaard FJ, van der Elst A, Mollema R, van Tets WF, Warner A, Joosten JJA, Amir MI, Haasbeek CJA, Smit EF, Slotman BJ, Senan S (2013) Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol 24(6):1543–1548. https://doi.org/10.1093/annonc/mdt026 (first published online February 20, 2013)

    Article  PubMed  CAS  Google Scholar 

  6. Palma DA, Senan S (2012) Early-stage non-small cell lung cancer in elderly patients: should stereotactic radiation therapy be the standard of care? Int J Radiat Oncol Biol Phys 84(5):1058–1059. https://doi.org/10.1016/j.ijrobp.2012.07.2353

    Article  PubMed  Google Scholar 

  7. Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M (2012) Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 17(8):1100–1107. https://doi.org/10.1634/theoncologist.2012-0092 (Epub 2012 Jun 20; Review)

    Article  PubMed  PubMed Central  Google Scholar 

  8. Guckenberger M, Andratschke N, Alheit H et al (2014) Definition of stereotactic body radiotherapy: Principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol 190(1):26–33. https://doi.org/10.1007/s00066-013-0450-y

    Article  PubMed  CAS  Google Scholar 

  9. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24(30):4833–4839

    Article  PubMed  Google Scholar 

  10. Li Q, Swanick CW, Allen PK, Gomez DR, Welsh JW, Liao Z, Balter PA, Chang JY (2014) Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications. Radiother Oncol 112(2):256–261. https://doi.org/10.1016/j.radonc.2014.07.010

    Article  PubMed  Google Scholar 

  11. Bral S, Gevaert T, Linthout N, Versmessen H, Collen C, Engels B, Storme G (2011) Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial. Int J Radiat Oncol Biol Phys 80(5):1343–1349

    Article  PubMed  Google Scholar 

  12. Mazzola R, Fiorentino A, Ricchetti F, Giaj Levra N, Fersino S, Di Paola G, Lo Casto A, Ruggieri R, Alongi F (2016) Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response. Br J Radiol 20:20160146

    Article  Google Scholar 

  13. Mazzola R, Fiorentino A, Di Paola G, Giaj Levra N, Ricchetti F, Fersino S, Tebano U, Pasetto S, Ruggieri R, Salgarello M, Alongi F (2017) Stereotactic ablative radiation therapy for lung oligometastases: predictive Parameters of early response by (18)FDG-PET/CT. J Thorac Oncol 12(3):547–555. https://doi.org/10.1016/j.jtho.2016.11.2234

    Article  PubMed  Google Scholar 

  14. Louie AV, Senan S, Patel P, Ferket BS, Lagerwaard FJ, Rodrigues GB, Salama JK, Kelsey C, Palma DA, Hunink MG (2014) When is a biopsy-proven diagnosis necessary before stereotactic ablative radiotherapy for lung cancer? A decision analysis. Chest 146(4):1021–1028. https://doi.org/10.1378/chest.13-2924

    Article  PubMed  Google Scholar 

  15. Marcenaro M, Vagge S, Belgioia L, Agnese D, Lamanna G, Mantero E, Gusinu M, Garelli S, Cavagnetto F, Agostinelli S, Corvò R (2013) Ablative or palliative stereotactic body radiotherapy with helical tomotherapy for primary or metastatic lung tumor. Anticancer Res 33(2):655–660

    PubMed  Google Scholar 

  16. Keall PJ, Mageras GS, Balter JM, Emery RS, Forster KM, Jiang SB, Kapatoes JM, Low DA, Murphy MJ, Murray BR, Ramsey CR, Van Herk MB, Vedam SS, Wong JW, Yorke E (2006) The management of respiratory motion in radiation oncology report of AAPM Task Group 76a). Med Phys 33:3874–3900. https://doi.org/10.1118/1.2349696

    Article  PubMed  Google Scholar 

  17. Chang HJ, Ko HL, Lee CY, Wu RH, Yeh YW, Jiang JS, Kao SJ, Chi K (2012) Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy. Radiat Oncol 27(7):222. https://doi.org/10.1186/1748-717X-7-222

    Article  Google Scholar 

  18. Arcangeli S, Agolli L, Portalone L, Migliorino MR, Lopergolo MG, Monaco A et al (2015) Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC. Br J Radiol 88:20140728

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Franks KN, Jain P, Snee MP (2015) Stereotactic ablative body radiotherapy for lung cancer. Clin Oncol (R Coll Radiol) 27(5):280–289. https://doi.org/10.1016/j.clon.2015.01.006 (Epub 2015 Mar 4)

    Article  CAS  Google Scholar 

  20. Navarria P, Ascolese AM, Tomatis S, Cozzi L, De Rose F, Mancosu P, Alongi F, Clerici E, Lobefalo F, Tozzi A, Reggiori G, Fogliata A, Scorsetti M (2014) Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiat Oncol 9(1):91. https://doi.org/10.1186/1748-717X-9-91

    Article  PubMed  PubMed Central  Google Scholar 

  21. Moustakis C, Blanck O, Ebrahimi Tazehmahalleh F, Ka Heng Chan M, Ernst I, Krieger T, Duma MN, Oechsner M, Ganswindt U, Heinz C, Alheit H, Blank H, Nestle U, Wiehle R, Kornhuber C, Ostheimer C, Petersen C, Pollul G, Baus W, Altenstein G, Beckers E, Jurianz K, Sterzing F, Kretschmer M, Seegenschmiedt H, Maass T, Droege S, Wolf U, Schoeffler J, Haverkamp U, Eich HT, Guckenberger M (2017) Planning benchmark study for SBRT of early stage NSCLC : results of the DEGRO Working Group Stereotactic Radiotherapy. Strahlenther Onkol 193(10):780–790. https://doi.org/10.1007/s00066-017-1151-8

    Article  PubMed  Google Scholar 

  22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026

    Article  PubMed  CAS  Google Scholar 

  23. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150S. https://doi.org/10.2967/jnumed.108.057307 (Review)

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Scorsetti M, Alongi F, Castiglioni S, Clivio A, Fogliata A, Lobefalo F, Mancosu P, Navarria P, Palumbo V, Pellegrini C, Pentimalli S (2011) Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments. Radiation oncology 6(1):113

    Article  PubMed  PubMed Central  Google Scholar 

  25. Navarria P, Ascolese AM, Mancosu P, Alongi F, Clerici E, Tozzi A, Iftode C, Reggiori G, Tomatis S, Infante M, Alloisio M (2013) Volumetric modulated arc therapy with flattening filter free (FFF) beams for stereotactic body radiation therapy (SBRT) in patients with medically inoperable early stage non small cell lung cancer (NSCLC). Radiother Oncol 107(3):414–418

    Article  PubMed  Google Scholar 

  26. Lischalk JW, Woo SM, Kataria S, Aghdam N, Paydar I, Repka MC, Anderson ED, Collins BT (2016) Long-term outcomes of stereotactic body radiation therapy (SBRT) with fiducial tracking for inoperable stage I non-small cell lung cancer (NSCLC). J Radiat Oncol 5:379–387. https://doi.org/10.1007/s13566-016-0273-4

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. De Bari B, Filippi AR, Mazzola R, Bonomo P, Trovò M, Livi L, Alongi F (2015) Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies. Cancer Treat Rev 41(6):511–518. https://doi.org/10.1016/j.ctrv.2015.04.002 (Epub 2015 Apr 16. Review)

    Article  PubMed  Google Scholar 

  28. Sterpin E, Janssens G, Orban de Xivry J, Goossens S, Wanet M, Lee JA, Delor A, Bol V, Vynckier S, Gregoire V, Geets X (2012) Helical tomotherapy for SIB and hypo-fractionated treatments in lung carcinomas: a 4D Monte Carlo treatment planning study. Radiother Oncol 104(2):173–180. https://doi.org/10.1016/j.radonc.2012.06.005

    Article  PubMed  Google Scholar 

  29. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Karasawa K, Hayakawa K, Niibe Y, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Kozuka T, Arimoto T, Hara R, Itami J, Araki T (2011) Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 81(5):1352–1358. https://doi.org/10.1016/j.ijrobp.2009.07.1751

    Article  PubMed  Google Scholar 

  30. Aoki M, Hatayama Y, Kawaguchi H, Hirose K, Sato M, Akimoto H, Fujioka I, Ono S, Tsushima E, Takai Y (2016) Clinical outcome of stereotactic body radiotherapy for primary and oligometastatic lung tumors: a single institutional study with almost uniform dose with different five treatment schedules. Radiat Oncol 20(11):5. https://doi.org/10.1186/s13014-016-0581-2

    Article  CAS  Google Scholar 

  31. Shibamoto Y, Hashizume C, Baba F, Ayakawa S, Miyakawa A, Murai T, Takaoka T, Hattori Y, Asai R (2015) Stereotactic body radiotherapy using a radiobiology-based regimen for stage I non-small-cell lung cancer: five-year mature results. J Thorac Oncol 10(6):960–964. https://doi.org/10.1097/JTO.0000000000000525

    Article  PubMed  CAS  Google Scholar 

  32. Hodge, Tome WA, Jaradat HA, Orton NP, Khuntia D, Traynor A, Weigel T, Mehta MP (2006) Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation. Acta Oncol 45(7):890–896 (NRO)

  33. Kim JY, Kay CS, Kim YS, Jang JW, Bae SH, Choi JY, Yoon SK, Kim KJ (2009) Helical tomotherapy for simultaneous multitarget radiotherapy for pulmonary metastasis. Int J Radiat Oncol Biol Phys 75(3):703–710. https://doi.org/10.1016/j.ijrobp.2008.11.065 (Epub 2009 May 4)

    Article  PubMed  Google Scholar 

  34. Sole CV, Lopez Guerra JL, Matute R, Jaen J, Puebla F, Rivin E, Sanchez-Reyes A, Beltran C, Bourgier C, Calvo FA, Marsiglia H (2013) Stereotactic ablative radiotherapy delivered by image-guided helical tomotherapy for extracranial oligometastases. Clin Transl Oncol 15(6):484–491. https://doi.org/10.1007/s12094-012-0956-2 (Epub 2012 Nov 10)

    Article  PubMed  CAS  Google Scholar 

  35. Aibe N, Yamazaki H, Nakamura S, Tsubokura T, Kobayashi K, Kodani N, Nishimura T, Okabe H, Yamada K (2014) Outcome and toxicity of stereotactic body radiotherapy with helical tomotherapy for inoperable lung tumor: analysis of Grade 5 radiation pneumonitis. J Radiat Res. 55(3):575–582. https://doi.org/10.1093/jrr/rrt146 (Epub 2014 Jan 23)

    Article  PubMed  PubMed Central  Google Scholar 

  36. Nagai A, Shibamoto Y, Yoshida M, Inoda K, Kikuchi Y (2014) Safety and efficacy of intensity-modulated stereotactic body radiotherapy using helical tomotherapy for lung cancer and lung metastasis. BioMed Res Int

  37. Rosen LR, Fischer-Valuck BW, Katz SR, Durci M, Wu HT, Syh J, Patel B (2013) Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center. Tumori 100(1):42–48

    Article  Google Scholar 

  38. Casutt A, Bouchaab H, Beigelman-Aubry C, Bourhis J, Lovis A, Matzinger O (2015) Stereotactic body radiotherapy with helical tomotherapy for medically inoperable early stage primary and second-primary non-small-cell lung neoplasm: 1-year outcome and toxicity analysis. Br J Radiol 88(1049):20140687. https://doi.org/10.1259/bjr.20140687 (Epub 2015 Mar 4)

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Guckenberger M, Baier K, Polat B, Richter A, Krieger T, Wilbert J, Mueller G, Flentje M (2010) Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiother Oncol 97(1):65–70. https://doi.org/10.1016/j.radonc.2010.04.027 (Epub 2010 Jun 3)

    Article  PubMed  Google Scholar 

  40. Ricardi U, Filippi AR, Guarneri A, Giglioli FR, Mantovani C, Fiandra C, Anglesio S, Ragona R (2009) Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy. Acta Oncol 48:571–577

    Article  PubMed  CAS  Google Scholar 

  41. Barriger RB, Forquer JA, Brabham JG, Andolino DL, Shapiro RH, Henderson MA, Johnstone PA, Fakiris AJ (2012) A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 82:457–462

    Article  PubMed  Google Scholar 

  42. Jo IY, Kay CS, Kim JY, Son SH, Kang YN, Jung JY, Kim KJ (2014) Significance of low-dose radiation distribution in development of radiation pneumonitis after helical-tomotherapy-based hypofractionated radiotherapy for pulmonary metastases. J Radiat Res 55(1):105–112. https://doi.org/10.1093/jrr/rrt080 (Epub 2013 Jun 11)

    Article  PubMed  Google Scholar 

  43. Wang Z, Zhu XX, Wu XH, Li B, Shen TZ, Kong QT, Li J, Liu ZB, Jiang WR, Wang Y, Hou B (2014) Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer. Am J Clin Oncol. 37(2):148–153. https://doi.org/10.1097/coc.0b013e31826e071b

    Article  PubMed  CAS  Google Scholar 

  44. Chi A, Ma P, Fu G et al (2013) Critical structure sparing in stereotactic ablative radiotherapy for central lung lesions: helical tomotherapy vs. volumetric modulated arc therapy. Chen C-T (ed) PLoS One 8(4):e59729. https://doi.org/10.1371/journal.pone.0059729

Download references

Acknowledgements

None of the authors involved in this study received financial support.

Author information

Authors and Affiliations

  1. Radiation Oncology School, University of Palermo, Palermo, Italy

    Vanessa Figlia, Francesco Cuccia, Vito Valenti & Antonio Lo Casto

  2. Radiation Oncology, Sacro Cuore Don Calabria Hospital, Verona, Negrar, Italy

    Rosario Mazzola & Filippo Alongi

  3. University of Brescia, Brescia, Italy

    Filippo Alongi

  4. Radiation Oncology, ARNAS-Civico Hospital, Palermo, Italy

    Gianluca Mortellaro, Daniela Cespuglio & Teresa Cucchiara

  5. Medical Physics Department, ARNAS-Civico Hospital, Palermo, Italy

    Giuseppina Iacoviello

  6. Radiology Department, ARNAS-Civico Hospital, Palermo, Italy

    Massimo Molino

  7. Medical Oncology Department, AO Ospedali Riuniti, Palermo, Italy

    Francesco Verderame

  8. Statistic Science Faculty, University of Palermo, Palermo, Italy

    Domenica Matranga & Giuseppe Ferrera

Authors
  1. Vanessa Figlia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rosario Mazzola
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Cuccia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Filippo Alongi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gianluca Mortellaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daniela Cespuglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Teresa Cucchiara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giuseppina Iacoviello
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Vito Valenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Massimo Molino
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Francesco Verderame
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Domenica Matranga
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Antonio Lo Casto
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Giuseppe Ferrera
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Cuccia.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Figlia, V., Mazzola, R., Cuccia, F. et al. Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experience. Radiol med 123, 406–414 (2018). https://doi.org/10.1007/s11547-018-0858-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11547-018-0858-7

Keywords

Search

Navigation